• Telo Genomics (TSXV:TELO) has revealed a collaboration agreement with Emery Pharma to enhance cellular and molecular bioanalytical solutions for clinical research
  • The agreement also provides the framework to develop collaborations and validate the utility of both companies’ platforms
  • Emery Pharma provides biologic drug development support and analytical characterization
  • Shares of Telo Genomics are up 3.03 per cent to C$0.17 as of 9:30 am ET

Telo Genomics (TSXV:TELO) has revealed a collaboration agreement with Emery Pharma to enhance cellular and molecular bioanalytical solutions for clinical research.

In a news release, the company stated the agreement also provides the framework to develop collaborations and validate the utility of both companies’ platforms.

Further, the partnership will also offer value-added information to address complex pharma and diagnostics unmet needs.

“We are thrilled that Telo has executed a collaboration agreement with a high-quality partner like Emery, the synergies between the technologies is compelling and we are looking forward to future developments,” Jay Wohlgemuth, managing partner of Trusted Health Advisors, a strategic advisor to Telo Genomics, said in a press release.

Telo Genomics capitalizes on telomere features as three-dimensional structural biomarkers quantified by its proprietary TeloView platform to inform on the level of genomic instability with high sensitivity. As such, the TeloView technology is conducted on the level of the single cell and is applicable to liquid biopsy.

Emery Pharma specializes in the characterization of biologics with an extensive array of services, ranging from intact mass analysis, peptide mapping, and glycan analysis, to host cell proteins, post-translational modifications and immunogenicity analysis, among others.

Telo Genomics is focused on its telomere platform in the industry with powerful applications and prognostic solutions.

Shares of Telo Genomics (TSXV:TELO) are up 3.03 per cent to C$0.17 as of 9:30 am ET.

Join the discussion: Find out what everybody’s saying about this stock on the Telo Genomics Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.


More From The Market Online

Cloud DX among leading remote patient monitoring suppliers in Canada

Cloud DX (TSXV:CDX) gives an update on its remote patient monitoring deal with the British Columbia Provincial Health Services Authority.

Reliq Health expands contract with U.S. health group

Reliq Health Technologies (TSXV:RHT) reveals it has expanded an existing contract with a large U.S. health group.